These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 32593547)

  • 41. Preliminary Investigation of Microbiome and Dietary Differences in Patients with Phenylketonuria on Enzyme Substitution Therapy Compared to Traditional Therapies.
    McWhorter N; Dhillon J; Hoffman J
    J Acad Nutr Diet; 2022 Jul; 122(7):1283-1295.e3. PubMed ID: 34968752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria.
    Wang L; Gamez A; Sarkissian CN; Straub M; Patch MG; Han GW; Striepeke S; Fitzpatrick P; Scriver CR; Stevens RC
    Mol Genet Metab; 2005; 86(1-2):134-40. PubMed ID: 16006165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new therapy prevents intellectual disability in mouse with phenylketonuria.
    Pascucci T; Rossi L; Colamartino M; Gabucci C; Carducci C; Valzania A; Sasso V; Bigini N; Pierigè F; Viscomi MT; Ventura R; Cabib S; Magnani M; Puglisi-Allegra S; Leuzzi V
    Mol Genet Metab; 2018 May; 124(1):39-49. PubMed ID: 29661557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic etiology and clinical challenges of phenylketonuria.
    Elhawary NA; AlJahdali IA; Abumansour IS; Elhawary EN; Gaboon N; Dandini M; Madkhali A; Alosaimi W; Alzahrani A; Aljohani F; Melibary EM; Kensara OA
    Hum Genomics; 2022 Jul; 16(1):22. PubMed ID: 35854334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study.
    Bratkovic D; Margvelashvili L; Tchan MC; Nisbet J; Smith N
    Metabolism; 2022 Mar; 128():155116. PubMed ID: 34973284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A microparticulate based formulation to protect therapeutic enzymes from proteolytic digestion: phenylalanine ammonia lyase as case study.
    Pereira de Sousa I; Gourmel C; Berkovska O; Burger M; Leroux JC
    Sci Rep; 2020 Feb; 10(1):3651. PubMed ID: 32107425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pah(enu2) mice.
    Rossi L; Pierigè F; Carducci C; Gabucci C; Pascucci T; Canonico B; Bell SM; Fitzpatrick PA; Leuzzi V; Magnani M
    J Control Release; 2014 Nov; 194():37-44. PubMed ID: 25151978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biochemical analysis of Centaurea depressa phenylalanine ammonia lyase (PAL) for biotechnological applications in phenylketonuria (PKU).
    Babaoğlu Aydaş S; Şirin S; Aslim B
    Pharm Biol; 2016 Dec; 54(12):2838-2844. PubMed ID: 27246528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria.
    Gámez A; Sarkissian CN; Wang L; Kim W; Straub M; Patch MG; Chen L; Striepeke S; Fitzpatrick P; Lemontt JF; O'Neill C; Scriver CR; Stevens RC
    Mol Ther; 2005 Jun; 11(6):986-9. PubMed ID: 15922970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: Evidence from dispensing data.
    Lah M; Cook K; Gomes DA; Liu S; Tabatabaeepour N; Kirson N; Chen E; Lindstrom K; Whitehall KB; Van Backle J; Burton BK
    Mol Genet Metab Rep; 2022 Dec; 33():100918. PubMed ID: 36176956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blood phenylalanine reduction reverses gene expression changes observed in a mouse model of phenylketonuria.
    Manek R; Zhang YV; Berthelette P; Hossain M; Cornell CS; Gans J; Anarat-Cappillino G; Geller S; Jackson R; Yu D; Singh K; Ryan S; Bangari DS; Xu EY; Kyostio-Moore SRM
    Sci Rep; 2021 Nov; 11(1):22886. PubMed ID: 34819582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
    Burton BK; Nowacka M; Hennermann JB; Lipson M; Grange DK; Chakrapani A; Trefz F; Dorenbaum A; Imperiale M; Kim SS; Fernhoff PM
    Mol Genet Metab; 2011 Aug; 103(4):315-22. PubMed ID: 21646032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nutrition management of PKU with pegvaliase therapy: update of the web-based PKU nutrition management guideline recommendations.
    Cunningham A; Rohr F; Splett P; Mofidi S; Bausell H; Stembridge A; Kenneson A; Singh RH
    Orphanet J Rare Dis; 2023 Jun; 18(1):155. PubMed ID: 37349772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Best practice recommendations for the management of anxiety during the pegvaliase journey.
    Bjoraker KJ; Eggerding C; Ellenberg E; Hollander S; Holmes BM; Lindstrom K; McNutt M; Miller S; Northrup H; Rogers M; Rose S; Scott M; Shim S; Wardley B; Wessenberg L; Bilder DA
    Mol Genet Metab; 2024 Jan; 141(1):107737. PubMed ID: 38043481
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Silk-Based Platform to Stabilize Phenylalanine Ammonia-lyase for Orally Administered Enzyme Replacement Therapy.
    d'Amone L; Trivedi VD; Nair NU; Omenetto FG
    Mol Pharm; 2022 Dec; 19(12):4625-4630. PubMed ID: 35862031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pegvaliase dose escalation to 80 mg daily may lead to efficacy in patients who do not exhibit an optimal response at lower doses.
    Vucko ER; Havens KE; Baker JJ; Burton BK
    Mol Genet Metab Rep; 2022 Sep; 32():100905. PubMed ID: 36046394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preservation of high phenylalanine ammonia lyase activities in roots of Japanese Striped corn: a potential oral therapeutic to treat phenylketonuria.
    López-Villalobos A; Lücker J; López-Quiróz AA; Yeung EC; Palma K; Kermode AR
    Cryobiology; 2014 Jun; 68(3):436-45. PubMed ID: 24657198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase.
    Sarkissian CN; Shao Z; Blain F; Peevers R; Su H; Heft R; Chang TM; Scriver CR
    Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2339-44. PubMed ID: 10051643
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain.
    Berguig GY; Martin NT; Creer AY; Xie L; Zhang L; Murphy R; Pacheco G; Bullens S; Olbertz J; Weng HH
    Mol Genet Metab; 2019 Dec; 128(4):422-430. PubMed ID: 31648944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report.
    Safos S; Chang TM
    Artif Cells Blood Substit Immobil Biotechnol; 1995; 23(6):681-92. PubMed ID: 8556141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.